English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatocellular carcinoma (HCC) is one the most common malignant tumors, with high rates of morbidity and mortality. Surgery is currently the only curative method for HCC. However, many patients are diagnosed with HCC at the advanced stage, and radical resection can no longer be performed. Patients with mildly advanced HCC cannot undergo hepatectomy, and thus transcatheter arterial chemoembolization (TACE) and/or biological targeted therapy are alternative options for these patients. In the present study, we report a patient who showed bene it from the combined treatment of TACE and crizotinib. General clinical data

annals of clinical gastroenterology and hepatology

Transcatheter arterial chemoembolization combined with molecular targeted therapy for a patient with hepatocellular carcinoma with intrahepatic metastasis and main portal vein tumor thrombus: A case report and literature review